Metastatic Hepatocellular Carcinoma (DBCOND0041971)

Identifiers

Synonyms

Hepatocellular Carcinoma Metastatic / Metastatic hepatocellular carcinoma / Metastatic hepatocellular carcinoma (disorder) / Metastatic hepatocellular carcinoma (morphologic abnormality) / Liver cell carcinoma / Primary liver cell carcinoma (disorder) / Hepatocellular carcinoma / Carcinoma hepatocellular / Hepatoma / Primary carcinoma of liver (disorder) / Liver carcinoma / Carcinoma liver / Liver cell carcinoma (disorder) / Hepatocellular carcinoma (morphologic abnormality) / Carcinoma of liver / Carcinoma, Hepatocellular

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Atezolizumab	A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.	Programmed cell death 1 ligand 1target Programmed cell death protein 1target
Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01839604	A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma	Danvatirsen	treatment	1	completed
NCT06066138	A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing	Atezolizumab	treatment	1	not_yet_recruiting
NCT06600321	A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma	Pembrolizumab	treatment	1	recruiting
NCT04514484	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Cabozantinib Nivolumab	treatment	1	active_not_recruiting
NCT03937830	Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma	Bevacizumab Doxorubicin Durvalumab Tremelimumab	treatment	2	recruiting
NCT04175912	Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver	Carboplatin Paclitaxel Pevonedistat	treatment	2	active_not_recruiting
NCT05003895	GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT05092373	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax	Albumin human Atezolizumab Cabozantinib Paclitaxel	treatment	1	recruiting
NCT06427941	A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors	Tislelizumab	treatment	1	recruiting
NCT06228326	A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs	No drug interventions	treatment	1	recruiting
NCT04221893	Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers	No drug interventions	treatment	Not Available	recruiting
NCT05075993	Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors	Bevacizumab Cyclophosphamide Exlinkibart Paclitaxel	treatment	1	recruiting
NCT00752063	Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma	Capecitabine Oxaliplatin Sorafenib	treatment	2	unknown_status
NCT06006286	A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma	Atezolizumab Bevacizumab Pegargiminase	treatment	1 / 2	withdrawn
NCT04828486	Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer	Futibatinib Pembrolizumab	treatment	2	recruiting
NCT05269381	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Cyclophosphamide Pembrolizumab Sargramostim	treatment	1 / 2	recruiting
NCT04511455	Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment	Cabozantinib	treatment	2	active_not_recruiting
NCT01754987	A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective	Ascorbic acid Sorafenib	treatment	1 / 2	completed
NCT05199285	A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab	Ipilimumab Nivolumab	treatment	2	recruiting
NCT04401800	Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma	Lenvatinib Tislelizumab	treatment	2	completed
NCT05168163	Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer	Atezolizumab Cabozantinib Lenvatinib	treatment	2	recruiting
NCT04025567	Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral	Vancomycin	treatment	2	withdrawn
NCT03893695	Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)	Ascrinvacumab Nivolumab	treatment	1 / 2	completed
NCT03695250	BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer	Linrodostat Nivolumab	treatment	1 / 2	terminated